# OnCo record nct07079475 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07079475/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07079475", "NCT07079475" ;
  schema:name "Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)"@en ;
  schema:alternateName "TIAN-SHAN8"@en ;
  schema:description "A phase 1/2 trial of Sunvozertinib, Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Dizal Pharmaceuticals, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07079475/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07079475> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2025-07-30" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/sunvozertinib/>, <https://onco.cc/drugs/osimertinib/> ;
  onco:companies <https://onco.cc/companies/dizal/> .